您好,欢迎您

【2025 ASCO】那些登顶NEJM的改变了治疗格局的研究

06月16日
来源:王一树


今年上榜ASCO,且NEJM同步发表多项改变临床实践的研究!

1. 铂类化疗后小细胞肺癌:Tarlatamab治疗


Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy


2. 高危皮肤鳞状细胞癌:辅助Cemiplimab或安慰剂


Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma


3. Elinzanetant治疗乳腺癌内分泌治疗所致血管舒缩症状


Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer


4. 胃癌及胃食管交界癌:围手术期Durvalumab治疗

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer


5. 肺癌:新辅助Nivolumab联合化疗的总生存期

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer


6. 胃癌:Trastuzumab Deruxtecan或

Ramucirumab联合紫杉醇

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer


7. 结肠癌辅助化疗后:结构化运动的作用


Structured Exercise after Adjuvant Chemotherapy for Colon Cancer


8. 晚期乳腺癌:PROTAC雌激素受体降解剂Vepdegestrant


Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer


9. 初发ESR1突变晚期乳腺癌一线Camizestrant治疗


First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer


10. PIK3CA突变晚期乳腺癌:Inavolisib的总生存期数据


Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer